版本:
中国

BRIEF-Immune Pharmaceuticals says board to pursue possible spin-off of Cytovia into separate, stand-alone company independent from Immune

April 24 Immune Pharmaceuticals Inc:

* Immune Pharmaceuticals announces corporate restructuring

* Board to pursue a possible spin-off of Cytovia into a separate, stand-alone company independent from immune

* Immune Pharmaceuticals Inc - Elliot Maza named interim CEO of Immune

* Immune Pharmaceuticals Inc - board has authorized Daniel Teper to lead company's oncology business

* Board of directors has authorized Dr. Daniel Teper to lead co's oncology business within cytovia, inc. Subsidiary

* Immune pharmaceuticals inc - board has accepted resignation of Daniel Teper as CEO of Immune, effective immediately

* Immune Pharmaceuticals Inc- Maza will resign from audit committee of board but will continue to serve as a director

* Immune Pharmaceuticals Inc - Teper will remain a member of company's board

* Immune Pharmaceuticals - intends to continue to focus on development of topical nano-cyclosporine for treatment of atopic dermatitis, moderate psoriasis Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐